Lucid Diagnostics Posts $1.5M Q4 EsoGuard Revenue, Secures VA Contract
Lucid Diagnostics recognized $1.5 million in fourth-quarter EsoGuard revenue and processed 3,664 tests, reflecting growing commercial uptake. The company secured a Department of Veterans Affairs contract to expand EsoGuard access to nine million veterans and reported positive real-world data from nearly 12,000 at-risk patients.
1. Q4 Financial Performance
For the quarter ended December 31, 2025, Lucid Diagnostics recognized $1.5 million in EsoGuard Esophageal DNA Test revenue and processed 3,664 tests, demonstrating increased adoption of its esophageal screening technology.
2. VA Contract Expansion
Lucid secured a contract with the U.S. Department of Veterans Affairs to deploy EsoGuard across the VA system, potentially granting access to approximately nine million veterans in the nation's largest integrated healthcare network.
3. Real-World Study Results
The company reported positive findings from the largest real-world evaluation of EsoGuard and its EsoCheck Esophageal Cell Collection Device, involving nearly 12,000 at-risk patients and confirming strong esophageal precancer detection performance.
4. Medicare Coverage Outlook
Lucid Diagnostics is pursuing transformative Medicare coverage for EsoGuard, which could significantly enhance reimbursement rates and drive broader clinician adoption once a draft policy is published.